Karyopharm Therapeutics, Inc. KPTI 深 沪
交易中 03-25 11:45:32 美东时间
5.305
-0.135
-2.48%
华盛通- 最 高5.71
- 今 开5.36
- 成交量 72.89万股
- 最 低 5.22
- 昨 收 5.44
- 总市值 9731.48万
- 52周最高 10.99
- 市盈率 静 --
- 换手率 3.97%
- 52周最低 3.56
- 委 比 -16.49%
- 总股本 1834.40万
- 历史最高 735.075
- 量 比 0.55
- 振 幅 9.01%
- 历史最低 5.14
- 每 手 1
- 风险率 1.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BUZZ-Street View: Karyopharm's cancer drug trial results limit regulatory odds
BUZZ-Street View: Karyopharm's cancer drug trial results limit regulatory odds ** Karyopharm Therapeutics KPTI.O said on Tuesday its therapy led to significant reduction in spleen size in a late-stage study of patients with myelofibrosis, a rare blood cancer, meeting only one of its two main goals *
今天 19:49
Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark
Karyopharm Therapeutics shares fall after mixed Phase 3 SENTRY data show spleen reduction gains but miss symptom endpoint.
今天 01:20
BUZZ-U.S. STOCKS ON THE MOVE-DexCom, Ocugen, Estee Lauder
BUZZ-U.S. STOCKS ON THE MOVE-DexCom, Ocugen, Estee Lauder Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 24 (Reuters) - U.S. stock index futures pointed to a lower open on
03-24 21:10
Karyopharm Therapeutics jumps 18%, raises $30M privately
Karyopharm Therapeutics (KPTI) announced a $30M private placement specifically with RA Capital and an additional ~$44M of gross proceeds if the accompanying warrants are exercised in full. In the pr...
03-24 19:57
Karyopharm血癌药物在研究中达成两大主要目标之一
Karyopharm治疗公司（Karyopharm Therapeutics）周二宣布，其一款肿瘤治疗药物在一项针对罕见血癌患者的晚期临床试验中，使患者脾脏...
03-24 19:48
UPDATE 2-Karyopharm's drug reduces spleen size in rare blood cancer study
UPDATE 2-Karyopharm's drug reduces spleen size in rare blood cancer study Adds shares in paragraph 2, details throughout March 24 (Reuters) - Karyopharm Therapeutics KPTI.O said on Tuesday its therapy for patients with a rare blood cancer showed a reduction in spleen size in a late-stage trial, meet
03-24 19:26
Karyopharm Announces $30 Million Private Placement with RA Capital
NEWTON, Mass., March 24, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that i...
03-24 19:01
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $175 price target and CROX has a Neutral rating.
03-10 20:50
Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer
Zevra Therapeutics announced the appointment of Justin Renz as Chief Financial Officer, effective March 9, 2026. With over 25 years of experience in the biopharmaceutical industry, Renz brings expertise in capital markets and strategic transactions. He previously served at Ardelyx, Correvio Pharma, Karyopharm Pharmaceuticals, and Zalicus Inc. Zevra, focused on rare disease therapies, aims to strengthen its financial foundation to advance innovati...
03-05 12:30
